Actively Negotiating the Mind-Body Divide: How Clozapine-Treated Schizophrenia Patients Make Health for Themselves.

Cult Med Psychiatry

Department of Anthropology, Australian National University, AD Hope Building, Canberra, 2612, Australia.

Published: September 2017

It is well recognised that antipsychotic treatments impact the whole body, not just the target area of the brain. For people with refractory schizophrenia on clozapine, the gold standard antipsychotic treatment in England and Australia, the separation of mental and physical regimes of health is particularly pronounced, resulting in multiple, compartmentalised treatment registers. Clinicians often focus on the mental health aspects of clozapine use, using physical indicators to determine whether treatment can continue. Our observations of 59 participants in England and Australia over 18 months revealed that patients did not observe this hierarchisation of mental treatments and physical outcomes. Patients often actively engaged in the management of their bodily symptoms, leading us to advance the figure of the active, rather than passive, patient. In our paper, we do not take the position that the facility for active management is a special one utilised only by these patients. We seek instead to draw attention to what is currently overlooked as an ordinary capacity to enact some sort of control over life, even under ostensibly confined and confining circumstances. We argue that clozapine-treated schizophrenia patients utilise the clinical dichotomy between mental and physical domains of health to rework what health means to them. This permits patients to actively manage their own phenomenological 'life projects' (Rapport, I am Dynamite: an Alternative Anthropology of Power, Routledge, London 2003), and forces us to reconsider the notion of clinical giveness of what health means. This making of one's own meanings of health may be critical to the maintenance of a sense of self.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11013-016-9517-4DOI Listing

Publication Analysis

Top Keywords

clozapine-treated schizophrenia
8
schizophrenia patients
8
england australia
8
mental physical
8
patients actively
8
health
7
patients
6
actively negotiating
4
negotiating mind-body
4
mind-body divide
4

Similar Publications

Background: Clozapine has demonstrated superiority in improving both positive and negative symptoms of treatment-resistant schizophrenia; however, there are associated treatment-limiting side effects, including myocarditis, cardiomyopathy and agranulocytosis.

Aim: This retrospective cohort study describes the prevalence of myocarditis, left ventricular (LV) dysfunction, cardiovascular risk factors and outcomes in a cohort of patients maintained on clozapine therapy.

Methods: Data were retrospectively collated from patients who had a diagnosis of schizophrenia, had been managed with clozapine at any stage during their care and undergone at least one echocardiogram.

View Article and Find Full Text PDF

Objectives: Clozapine is an atypical antipsychotic crucial for treatment-resistant schizophrenia, characterised by its multi-receptor targeting, including serotonin (5-HT2A, 5-HT2C) and dopamine (D1, D2, D3, D4) receptors, among others. This broad mechanism is effective against positive symptoms of schizophrenia with a lower incidence of extrapyramidal side effects. However, clozapine poses significant haematological risks, notably agranulocytosis, necessitating stringent blood monitoring protocols.

View Article and Find Full Text PDF

Glutamate, GABA and NAA in treatment-resistant schizophrenia: A systematic review of the effect of clozapine and group differences between clozapine-responders and non-responders.

Behav Brain Res

February 2025

Mental Health Centre Glostrup, Copenhagen University Hospital - Mental Health Services CPH, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, Copenhagen 2200, Denmark.

Article Synopsis
  • Treatment-resistance in schizophrenia poses significant challenges, particularly for patients who do not respond to clozapine, with emerging research suggesting potential glutamatergic and GABAergic imbalances in these individuals.
  • A systematic review analyzed nine studies using proton magnetic resonance spectroscopy (H-MRS) to assess the impact of clozapine on brain metabolite levels in treatment-resistant (TRS) and ultra-treatment-resistant schizophrenia (UTRS) patients, following PRISMA guidelines.
  • The findings suggest clozapine may lower glutamate levels in specific brain areas while possibly increasing GABA and N-acetylaspartate (NAA), highlighting the need for more comprehensive studies to better understand these effects and their implications for
View Article and Find Full Text PDF

Purpose: Clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia in the United States (US). There were few randomized trials before its approval and potentially lethal clozapine adverse drug reactions (ADRs), such as agranulocytosis and myocarditis were identified by pharmacovigilance. VigiBase, the WHO global database, is a cornerstone of international pharmacovigilance efforts for ADR identification during post-marketing surveillance.

View Article and Find Full Text PDF
Article Synopsis
  • Clozapine is effective for treatment-resistant schizophrenia but can cause significant side effects, notably excessive daytime sleepiness, which is a form of hypersomnolence.
  • A systematic review examined how clozapine affects objective measures of hypersomnolence, analyzing six studies using various testing methods like polysomnography (PSG).
  • Initial findings showed clozapine led to longer sleep times and quicker sleep onset, but these effects did not last beyond 4-6 weeks, indicating a need for further long-term research on sleep patterns and wakefulness in clozapine-treated patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!